Steatotic Liver Disease: What You Need to Know, Part 1. Steatotic Liver Disease at the Crossroads—Bridging Alcohol-Associated Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Era of Multimorbidity
Nov
08
2025
Convention Center: Ballroom A, Level 3
8:00 AM - 9:30 AM
World Class Speakers
Description
Speakers delve into the intersections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on how multimorbidity—such as obesity, diabetes, and cardiovascular disease—complicates diagnosis, management, and prognosis. Experts discuss the shared and unique pathophysiological mechanisms, the role of genetic and behavioral risk factors, and the importance of a multidisciplinary approach to patient care.Presentations
8:00 AM - 8:15 AM
Nov
08
2025
San Diego, CA
Genetic Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease, MetALD, and Alcohol-Associated Liver Disease: Should It Be Incorporated Into Clinical Practice?
Veeral Ajmera, MD, Presenter
ALD
MASLD
8:15 AM - 8:30 AM
Nov
08
2025
San Diego, CA
Pediatric Steatotic Liver Disease: What's New and Where Should We Go Next?
Miriam B. Vos, MD, MSPH, FAASLD, Presenter
ALD
MASLD
8:30 AM - 8:45 AM
Nov
08
2025
San Diego, CA
Screening and Risk Stratification in MetALD: How to Account for Multiple Contributors of Disease?
Brian P Lee, MD, Presenter
ALD
MASLD
8:45 AM - 9:00 AM
Nov
08
2025
San Diego, CA
Steatotic Liver Disease: Role of Behavioral Health in Managing Weight and Alcohol Use
Gerald Scott Winder, MD MSc FACLP, Presenter
ALD
MASLD
9:00 AM - 9:15 AM
Nov
08
2025
San Diego, CA
Natural History and Disease Progression of MetALD
Juan Pablo Arab, MD, FRCPC, Presenter
ALD
MASLD
9:15 AM - 9:30 AM
Nov
08
2025
San Diego, CA
Q&A Session
Elizabeth Lee, MN, NP, CGN(C), Moderator
ALD
MASLD
Objectives
- Explain the connections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), including their overlapping risk factors and pathways.
- Review the role of multimorbidity in shaping disease outcomes in steatotic liver diseases.
- Discuss strategies for integrating ALD and MASLD management into clinical practice.
Chair
Mazen Noureddin, MD, MHSc
Houston Methodist Hospital
Chair
Juan Pablo Arab, MD, FRCPC
Virginia Commonwealth University